Serviceeinschränkungen vom 12.-22.02.2026 - weitere Infos auf der UB-Homepage
American Psychological Association 6th edition

Peng, T.-R., Weng, Y.-F., Wu, T.-W., Wu, C.-C., Hsu, C.-L., & Hsu, C.-S. (2025). Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 17(13), 2110-2125. https://doi.org/10.3390/cancers17132110

ISO-690 (author-date, English)

PENG, Tzu-Rong, WENG, Yi-Fang, WU, Ta-Wei, WU, Chao-Chuan, HSU, Chia-Lu und HSU, Ching-Sheng, 2025. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 1 Juli 2025. Vol. 17, no. 13, p. 2110-2125. DOI 10.3390/cancers17132110.

Modern Language Association 9th edition

Peng, T.-R., Y.-F. Weng, T.-W. Wu, C.-C. Wu, C.-L. Hsu, und C.-S. Hsu. „Efficacy of Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.“. Cancers, Bd. 17, Nr. 13, Juli 2025, S. 2110-25, https://doi.org/10.3390/cancers17132110.

Mohr Siebeck - Recht (Deutsch - Österreich)

Peng, Tzu-Rong/Weng, Yi-Fang/Wu, Ta-Wei/Wu, Chao-Chuan/Hsu, Chia-Lu/Hsu, Ching-Sheng: Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., Cancers 2025, 2110-2125.

Emerald - Harvard

Peng, T.-R., Weng, Y.-F., Wu, T.-W., Wu, C.-C., Hsu, C.-L. und Hsu, C.-S. (2025), „Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.“, Cancers, Vol. 17 No. 13, S. 2110-2125.

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.